Join Biora Therapeutics for a virtual KOL event featuring Bruce Sands, MD, MS (Icahn School of Medicine at Mount Sinai) and Brian Feagan, MD, FRCPC (Schulich School of Medicine & Dentistry at the University of Western Ontario), who will discuss the unmet need and current treatment landscape for patients with ulcerative colitis (UC), as well as the value of colonic drug delivery for improving efficacy.

Biora leadership will highlight key results from the Phase 1 single and multiple ascending dose (SAD/MAD) clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment of patients with UC. BT-600 leverages Biora’s ingestible NaviCap™ device to deliver a proprietary liquid formulation of tofacitinib directly to the colon.

A live question and answer session will follow the formal presentations.